Trial reportBritish journal of clinical pharmacology2008
Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.
Trial report in British journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 82 citations in OpenAlex.
- Bioequivalence evaluation of generic febuxostat versus FeburicBMC pharmacology & toxicology · 2025Trial
- Trial
- Pharmacokinetics, pharmacodynamics, and tolerability of LC350189, a novel xanthine oxidase inhibitor, in healthy subjects.Drug design, development and therapy · 2015Trial
- Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.British journal of clinical pharmacology · 2010Trial
- Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects.British journal of clinical pharmacology · 2008Trial
- Article
- Enhancing Febuxostat Solubility Through Cocrystal Formation: Role of Substrate Selection and Amide Coformers.International journal of molecular sciences · 2025Article
- An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction.Pharmacology research & perspectives · 2024Article
- Population pharmacokinetic analysis of febuxostat with high focus on absorption kinetics and food effect.BMC pharmacology & toxicology · 2024Article
- Evaluation of Pharmacokinetic Feasibility of Febuxostat/L-pyroglutamic Acid Cocrystals in Rats and Mice.Pharmaceutics · 2023Article
- Population pharmacokinetic modelling of febuxostat in healthy subjects and people with gout.British journal of clinical pharmacology · 2022Article
- Review
- Design and Optimization of Febuxostat-loaded Nano Lipid Carriers Using Full Factorial Design.Turkish journal of pharmaceutical sciences · 2021Article
- A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects.British journal of clinical pharmacology · 2020Article
- Side Effects and Interactions of the Xanthine Oxidase Inhibitor Febuxostat.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Physicochemical properties of dietary phytochemicals can predict their passive absorption in the human small intestine.Scientific reports · 2017Article
- Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.Clinical pharmacokinetics · 2017Review
- Urate-lowering therapy: current options and future prospects for elderly patients with gout.Drugs & aging · 2014Review
- Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals.Experimental and therapeutic medicine · 2014Article
- Bioequivalance and pharmacokinetic study of febuxostat in human plasma by using LC-MS/MS with liquid liquid extraction method.SpringerPlus · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledWhat is already known about this subject. Febuxostat is a novel nonpurine selective inhibitor of xanthine oxidase. What this study adds. This is the first manuscript to address the effect of food and antacid on the pharmacokinetics and/or pharmacodynamics of febuxostat. The study will determine whether the drug can be administered regardless of food or antacid. It will therefore influence how the drug should be administered.
aimsTo evaluate the effects of food or antacid on the pharmacokinetics and/or pharmacodynamics of febuxostat.
methodsFour Phase I, two-period, crossover studies were performed in healthy male and female subjects. Subjects either received single 40-mg (n = 24), multiple 80-mg (n = 24) and single 120-mg (n = 20) doses of febuxostat in fasting and nonfasting conditions, or received single 80-mg (n = 24) doses alone or with antacid.
resultsFood caused a decrease in C(max) (38-49%) and AUC (16-19%) of febuxostat at different dose levels following single or multiple oral dosing with febuxostat. However, a slightly greater percent decrease in serum uric acid concentrations (58% vs. 51%) after multiple dosing with 80 mg of febuxostat under nonfasting conditions was observed, which was statistically (P < 0.05) but not clinically significant. Antacid caused a decrease in C(max) (32%), but had no effect on AUC of febuxostat. Febuxostat was safe and well tolerated in all studies.
conclusionsEven though food caused a decrease in the rate and extent of absorption of febuxostat, this decrease was not associated with a clinically significant change in febuxostat pharmacodynamic effect. Despite a decrease in the absorption rate of febuxostat, antacid had no effect on the extent of febuxostat absorption. Therefore, febuxostat can be administered regardless of food or antacid intake.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.